Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Nonpeptide agent · Amino acid or derivative
Detailed molecular class: Nonpeptide agent; see mechanism for subtype
Supplied sequence or chemical reference
PubChem CID: 6262
Molecular formula: C5H12N2O2
IUPAC: (2S)-2,5-diaminopentanoic acid
Source: PC-ORNITHINE
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
Non-proteinogenic urea-cycle amino acid; distinct from arginine and combination salts.
Evidence and critical reading
Reported scientific and empirical uses
Replacement and nutritional context · Sleep and circadian rhythms
Promoted for recovery/sleep and found in blends; shared effects across formulations have not been demonstrated.
Human evidence
A 28-adult crossover trial evaluated 400 mg orally for seven days and a melatonin-phase marker. A small phase shift does not establish an insomnia cure.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
A 28-adult crossover trial evaluated 400 mg orally for seven days and a melatonin-phase marker. A small phase shift does not establish an insomnia cure.
A 28-adult crossover trial evaluated 400 mg orally for seven days and a melatonin-phase marker. A small phase shift does not establish an insomnia cure.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by A randomized, double-blind and placebo-controlled crossover trial on the effect of l-ornithine ingestion on the human circadian clock.
400 mg · Total daily amount
- Frequency
- Daily
- Duration
- 7 days
- Route
- Oral
- Context
- 28 adults; circadian marker, not a confirmatory insomnia trial.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID29969301 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
The brief trial does not establish chronic safety, parenteral combination safety or a multinutrient-blend dose.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Ornithine · 125 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07876323 · Randomized Split-Face Controlled Study to Evaluate the Effectiveness of Topical Eflornithine 9.58% + Hydroquinone 4% + Fluocinolone 0.01% as Compared to Topical Tretinoin 0.05% + Hydroquinone 4% + Fluocinolone 0.01% for the Treatment of MelasmaRegistry status: CompletedLast update posted: October 15, 2026Query verification: October 16, 2026
NCT05737030 · Effect of L-ornithine-L-aspertate (LOLA) on the Gut MicrobiomeRegistry status: CompletedLast update posted: October 9, 2026Query verification: October 16, 2026
NCT07321912 · Eflornithine (DFMO) for Ewing Sarcoma and OsteosarcomaRegistry status: RecruitingLast update posted: October 6, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PC-ORNITHINE
PubChem L-ornithine (CID 6262)
October 16, 2026
- PMID29969301
Fukuda T, Haraguchi A, Takahashi M, Nakaoka T, Fukazawa M, Okubo J, Ozaki M, Kanatome A, Ohya R, Miura Y, Obara K, Shibata S.
October 16, 2026
- SEARCH-PUBMED-ornithine
PubMed/MED targeted search: TITLE_ABS:"L-ornithine" AND TITLE_ABS:sleep AND TITLE_ABS:randomized
October 16, 2026